New alliance will target major risk factor for Alzheimer's

Share this article:

A new collaboration will see four leading academic research laboratories working with AstraZeneca to study a major risk factor for Alzheimer's disease. Steven Paul, M.D., of Weill Cornell Medical College and AstraZeneca jointly announced the A5 Alliance. Collectively, the alliance will examine the apolipoprotein E4 genotype (ApoE). “We are convinced that ApoE represents a major piece of the Alzheimer's disease puzzle,” Paul noted. Additional members include David Holtzman, M.D. of Washington University in St. Louis, Peter Davies, Ph.D., of The Feinstein Institute for Medical Research and Cheryl Wellington, Ph.D., of the University of British Columbia.

Share this article:
close

Next Article in Products

More in Products

Last day to enter McKnight's Tech Awards

Today is the final day to submit entries into the third annual McKnight's Excellence in Technology Awards.

AliMed offers three new fall management products

AliMed offers three new fall management products

AliMed is now offering the AliMed CordLess® Sensor Alarm and the AliMed Worry-Free Fall Alarm to help reduce the risk of accidental falls, and the HipShield® X-tra to help prevent ...

Diamond Wipes creates new wipes

Diamond Wipes creates new wipes

Diamond Wipes has announced an updated version of its Handyclean™ cleaning and sanitizing wipes.